Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Urothelial Carcinoma |
Dose: Intravenous Injection – 840 mg Frequency: every 2 weeks Note: Administer intravenously over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. |
|
Indication: Urothelial Carcinoma |
Dose: Intravenous Injection – 1200 mg Frequency: every 3 weeks Note: Administer intravenously over 60 minutes; if the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Alveolar Soft Part Sarcoma Age: Adult |
Dose: Intravenous – 15 mg/kg (not to exceed 1,200 mg) Frequency: every 3 weeks Duration: Continue until disease progression or unacceptable toxicity |
|
Indication: Alveolar Soft Part Sarcoma Age: greater than 2 years |
Dose: Intravenous – 15 mg/kg (not to exceed 1,200 mg) Frequency: every 3 weeks Duration: Continue until disease progression or unacceptable toxicity |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment: Mild or moderate (estimated glomerular filtration rate 30-89 mL/min/1.73 m2) |
Dose: Not mentioned Note: No dose adjustment is recommended |
|
Condition: Renal impairment: Severe (estimated glomerular filtration rate less than 20 mL/min/1.73 m2) |
Dose: Not mentioned Note: Not studied |
Administration
- Given as IV infusion over 60 minutes
- First infusion over 60 minutes
Side Effect
- Fatigue (52%)
- Decreased appetite (24-26%)
- Nausea (22-25%)
- Diarrhea (18-24%)
- Urinary Tract Infection (UTI) (17-22%)
- Constipation (15-21%)
- Pyrexia (14-21%)
- Back/neck pain (15-18%)
- Pruritus (13-18%)
- Peripheral edema (17-18%)
- Rash (15-17%)
- Vomiting (16-17%)
- Abdominal pain (15-17%)
- Dyspnea (12-16%)
- Cough (14%)
- Hyponatremia, Grade 3 or 4 (15%)
- Arthralgia (13-14%)
- Hematuria (14%)
- Anemia (67-83%)
- Hyperglycemia (61%)
- Neuropathy (56%)
- Increased BUN (52%)
- Neutropenia (52%)
- Fatigue/asthenia (44-50%)
- Lymphocytopenia (49%)
- Alopecia (48%)
- Lymphopenia (48%)
- Hypoalbuminemia (40-48%)
- Hyponatremia (38-42%)
- Myalgia/pain (42%)
- Hypomagnesemia (26-42%)
- Increased AST (31-40%)
- Nausea (18-39%)
- Increased alkaline phosphatase (39%)
- Increased ALT (27-37%)
- Diarrhea (16-33%)
- Neutropenia, Grade 3 or 4 (31%)
- Increased TSH (30%)
- Constipation (18-30%)
- Decreased appetite (23-29%)
- Hyperkalemia (28%)
- Increased creatinine (23-28%)
- Hypocalcemia (26%)
- Arthralgia (26%)
- Cough (20-26%)
- Hypertension (25%)
- Hyperphosphatemia (25%)
- Hypophosphatemia (25%)
- Hypokalemia (23%)
- Rash (12-23%)
- Dyspnea (22%)
- Pyrexia (18-19%)
- Vomiting (19%)
- Epistaxis (17%)
- Lymphopenia, Grade 3 or 4 (17%)
- Proteinuria (16%)
- Headache (16%)
- Arthralgia (1-12%)
- Alopecia (56%)
- Fatigue (47%)
- Peripheral neuropathies (47%)
- Nausea (46%)
- Diarrhea (33%)
- Anemia (28%)
- Constipation (25%)
- Headache (23%)
- Neutropenia (21%)
- Vomiting (20%)
- Decreased appetite (20%)
- Pyrexia (19%)
- Arthralgia (18%)
- Rash (17%)
- Peripheral edema (15%)
- Back pain (15%)
- Myalgia (14%)
- Pruritus (14%)
- Dizziness (14%)
- Dysgeusia (14%)
- Hypothyroidism (14%)
- Decreased neutrophils (13%)
- Urinary Tract Infection (UTI) (12%)
- Asthenia (12%)
- Pain in extremity (11%)
- Upper respiratory infection (11%)
- Nasopharangitis (11%)
- Anemia (94%)
- Neutropenia (73%)
- Hyperglycemia (67%)
- Thrombocytopenia (58%)
- Lymphopenia (46%)
- Neutropenia, Grade 3-4 (45%)
- Increased alkaline phosphatase (38%)
- Fatigue/asthenia (39%)
- Nausea (38%)
- Alopecia (37%)
- Hyponatremia (34%)
- Hypoalbuminemia (32%)
- Hypomagnesemia (31%)
- Decreased TSH (28%)
- Decreased appetite (27%)
- Constipation (26%)
- Hypocalcemia (26%)
- Increased ALT (26%)
- Increased AST (22%)
- Increased blood creatinine (22%)
- Neutropenia (22%)
- Hyperphosphatemia (21%)
- Increased TSH (21%)
- Thrombocytopenia, Grade 3-4 (20%)
- Vomiting (20%)
- Anemia, Grade 3-4 (17%)
- Hyponatremia, Grade 3-4 (15%)
- Lymphopenia, Grade 3-4 (14%)
- Hyperglycemia, Grade 3-4 (10%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity
|
Risk of severe immune reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 2°C-8°C. Atezolizumab should be protected from light. Do not freeze. Do not shake.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.